

Our Mission

To provide innovative non-viral vehicles to deliver nucleic acid therapeutics.

The Problem


Nucleic acid therapeutics (NATs) and gene therapy strategies have emerged among the most relevant technological breakthroughs in decades. However, the **clinical translation and impact** of these therapeutics relies on suitable **delivery** approaches. Efficiency and safety limitations arise from currently used viral and non-viral vectors, which are employed to deliver therapeutic cargos to their site of action and avoid their premature degradation.

Our Solution

Innovative peptide-amphiphile vehicles for non-toxic and efficient delivery of nucleic acid therapeutics and gene therapy tools *in vitro* and *in vivo*. These features are combined with a technical competitive advantage in the formulation step and a high cargo versatility that **broadens the scope** of the delivery applications. This approach will ultimately impact in more nucleic acid therapeutics reaching the clinic and helping patients in need.

Our Value Proposition

A **proprietary technology platform** that allows the straightforward synthesis of dynamic peptide-amphiphile libraries (>200 candidates) with **unique control** on their **chemical properties**. These vehicles can be rapidly screened for nucleic acid delivery efficiency to identify lead candidates for **tailored *in vitro* or *in vivo*** applications.



Differential features

- Structure-activity **optimization** at the **atomic level** (drug discovery-like)
- A straightforward PEG-free formulation: **single vehicle + cargo**
- Cargo versatility**: pDNA, mRNA, siRNA and Cas9 RNP
- A **well differentiated IP** position from mainstream delivery trends (LNPs)
- In vivo** validation (mRNA vaccination → IgG generation)

Our Business Model

- Sales** of research-grade peptide-amphiphile vehicle products for ***in vitro* transfection**
- Screening** services and selection of the most appropriate peptide-amphiphile combination for **tailored *in vitro* or *in vivo* nucleic acid delivery**. Supply under a research use license
- Licensing and **partnering for clinical development** of NATs and gene therapeutics and subsequent commercialization

Creation of a NewCo underway

Team



Javier Montenegro, PhD
CSO



Marisa Juanes, PhD
CTO



Alberto Fuertes, PhD
COO



Irene Lostalé-Seijo, PhD
Project leader

Contact information

Alberto Fuertes

alberto.fuertes@traffikgene.com | +34 881 81 57 57 | www.traffikgene.com

Partnering & Funding

